Some recent developments in treatment planning software and methodology for BNCT
- and others
Over the past several years the Idaho National Engineering Laboratory (INEL) has led the development of a unique, internationally-recognized set of software modules (BNCT-rtpe) for computational dosimetry and treatment planning for Boron Neutron Capture Therapy (BNCT). The computational capability represented by this software is essential to the proper administration of all forms of radiotherapy for cancer. Such software addresses the need to perform pretreatment computation and optimization of the radiation dose distribution in the target volume. This permits the achievement of the optimal therapeutic ratio (tumor dose relative to critical normal tissue dose) for each individual patient via a systematic procedure for specifying the appropriate irradiation parameters to be employed for a given treatment. These parameters include angle of therapy beam incidence, beam aperture and shape, and beam intensity as a function of position across the beam front. The INEL software is used for treatment planning in the current series of human glioma trials at Brookhaven National Laboratory (BNL) and has also been licensed for research and developmental purposes to several other BNCT research centers in the US and in Europe.
- Research Organization:
- Brookhaven National Lab. (BNL), Upton, NY (United States); Idaho National Lab. (INL), Idaho Falls, ID (United States)
- Sponsoring Organization:
- USDOE Office of Energy Research, Washington, DC (United States)
- DOE Contract Number:
- AC02-76CH00016; AC07-94ID13223
- OSTI ID:
- 539846
- Report Number(s):
- BNL-64624; CONF-9609293-; ON: DE97008898; TRN: 98:008396
- Resource Relation:
- Conference: 7. international symposium on neutron capture therapy for cancer, Zurich (Switzerland), 4-7 Sep 1996; Other Information: PBD: 1996
- Country of Publication:
- United States
- Language:
- English
Similar Records
Comparison of TORT and MCNP dose calculations for BNCT treatment planning
The BCNT treatment planning for the Brookhaven trials on human gliomas